Navigation Links
Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009
Date:12/10/2008

ity 6,505,000 15,595,000 TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $21,747,000 $23,057,000

    PEREGRINE PHARMACEUTICALS, INC.

    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

                               THREE MONTHS ENDED         SIX MONTHS ENDED

                           October 31,  October 31,  October 31,  October 31,
                              2008        2007          2008         2007
                           Unaudited    Unaudited     Unaudited    Unaudited

    REVENUES:
    Contract manufacturing
     revenue                $983,000   $1,863,000   $2,176,000    $3,484,000
    Government contract
     revenue                 958,000            -    1,282,000             -
    License revenue                -       29,000            -        33,000
       Total revenues      1,941,000    1,892,000    3,458,000     3,517,000

    COSTS AND EXPENSES:
    Cost of contract
     manufacturing           663,000    1,402,000    1,566,000     2,583,000
    Research and
     development           4,301,000    5,100,000    8,369,000     8,724,000
    Selling, general and
     administrative        1,527,000    1,943,000    3,233,000     3,651,000

       Total costs and
        expenses           6,491,000    8,445,000   13,168,000    14,958,000

    LOSS FROM OPERATIONS  (4,550,000)  (6,553,000)  (9,710,000)  (11,441,000)

    OTHER INCOME (EXPENSE):
    Interest and other
     income                   53,000      353,000      128,000       592,000
    Interest and other
     expense                       -       (7,000)      (1,000)      (14,000)

    NET LOSS             $(4,497,000) $(6,207,000) $(9,583,000) $(10,863,000)

    weighted average
       COMMON shares
        outstanding:
        Basic and
         Diluted         226,210,617  226,210,617  226,210,617   216,141,092

      BASIC AND DILUTED

'/>"/>
SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine news :

1. Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies
2. Data Published in Nature Medicine Highlights Ability of Peregrine Pharmaceuticals Bavituximab to Cure Lethal Virus Infections
3. Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials
4. Peregrine Pharmaceuticals Receives Approval to Begin New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
5. Positive Results From Peregrine Pharmaceuticals Bavituximab Phase l HCV Trial Presented at AASLD Meeting
6. Celator(R) Pharmaceuticals Presents Phase 1 Results With CPX-351 in Patients With Advanced Leukemia at the American Society of Hematology Meeting
7. Arena Pharmaceuticals to Host Research & Development Day on December 15, 2008
8. Arena Pharmaceuticals Announces Lorcaserin Phase 2b Clinical Trial Results Published in Obesity
9. Savient Pharmaceuticals to Present at the 27th Annual J.P. Morgan Healthcare Conference on January 14th
10. ISTA Pharmaceuticals to Participate at the RBC Capital Markets Healthcare Conference
11. Middlebrook Pharmaceuticals Opens Administrative and Sales Office in Westlake, Texas
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/30/2014)... (PRWEB) August 30, 2014 Ticket ... U.S. Open Tennis Championship tickets in NYC. ... promo/coupon code US-OPEN-2014 for all day session, evening session, ... group sales for this prestigious Grand Slam Tournament. , ... , 8/30/14 , US Open Tennis Championship: Men's/Women's 3rd ...
(Date:8/30/2014)... August 30, 2014 After offering ... country for the past several years, Dr. Roy ... Center have announced a scholarship program for veterans ... follows a meeting held this summer to discuss ... years, reporters have shed light on the large ...
(Date:8/30/2014)... TX (PRWEB) August 30, 2014 ... Disruptor Industry, 2009-2019 is a professional and in-depth ... industry. The report firstly reviews the basic information ... manufacturing technology. The report then explores global and ... product specification, capacity, Production value, and market share ...
(Date:8/30/2014)... 2014 Hundreds of Byetta lawsuits ( ... move forward in U.S. courts, Bernstein Liebhard LLP reports. ... July 31, 2014, Byetta and Bydureon (an extended-release version ... claims that allege the drugs caused pancreatitis, pancreatic cancer ... these claims are pending in a multidistrict litigation underway ...
(Date:8/30/2014)... Rapids, MI (PRWEB) August 30, 2014 ... residents, Forefront Dermatology is expanding with the addition of ... Dr. David Hammond who has provided leading-edge skin care ... with Forefront Dermatology. , “As a doctor, my ... they deserve. Through partnering with Forefront Dermatology, I’m better ...
Breaking Medicine News(10 mins):Health News:US Open Tennis Tickets: Ticket Down Slashes Ticket Prices for Labor Day Weekend Sessions and More 2Health News:US Open Tennis Tickets: Ticket Down Slashes Ticket Prices for Labor Day Weekend Sessions and More 3Health News:US Open Tennis Tickets: Ticket Down Slashes Ticket Prices for Labor Day Weekend Sessions and More 4Health News:US Open Tennis Tickets: Ticket Down Slashes Ticket Prices for Labor Day Weekend Sessions and More 5Health News:Tennessee Hyperbaric Center Offering HBOT Scholarships to Veterans 2Health News:Cell Disruptor Industry Global and Chinese Analysis for 2009-2019 in New Research Report at ReportsnReports.com 2Health News:Cell Disruptor Industry Global and Chinese Analysis for 2009-2019 in New Research Report at ReportsnReports.com 3Health News:Cell Disruptor Industry Global and Chinese Analysis for 2009-2019 in New Research Report at ReportsnReports.com 4Health News:Byetta Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Settlements in More than 80 Cases 2Health News:Byetta Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Settlements in More than 80 Cases 3Health News:Expanding Care at the Forefront of Dermatology 2
... choice is influenced by physicians, preferences, research suggests ... kind of treatment received by a prostate cancer patient ... patient,s care, new research shows. , U.S. researchers analyzed ... and older who were diagnosed with prostate cancer between ...
... among normal-weight patients , TUESDAY, March 9 (HealthDay News) ... obese face tougher survival odds following treatment compared with ... finding builds on prior research that established that being ... the first place. , "Previous studies have shown that ...
... The ... health, fertility health, and women,s health. , ... Edmonton, Alberta (PRWEB) March 9, 2010 -- The Pregnancy Health ... gives Canadian women important and potentially life-changing information about pregnancy health, fertility health, and ...
... ... Nine innovative healthcare companies have been named Finalists and ... at the 12th Annual Innovations in HealthcareSM Awards Event, on April ... awards honor companies which have proven ways to lower the cost ...
... ... (APNY), a group of 18 established and highly regarded pediatrics practices in Queens, Nassau and ... of their care to extend to thousands more New York children than in the past. ... (Vocus) March 9, 2010 ...
... ... & Cold and Allergy Conference. It is a nasal-sinus irrigation system with a patented ... risk of sinus re-infection, growing concerns in the medical community. The device is also ... ...
Cached Medicine News:Health News:Doctor's Specialty Often Steers Prostate Cancer Care 2Health News:Obese Colon Cancer Survivors Face Poorer Prognosis 2Health News:Obese Colon Cancer Survivors Face Poorer Prognosis 3Health News:Obese Colon Cancer Survivors Face Poorer Prognosis 4Health News:Pregnancy Health Centre Launches Website to Help Women 2Health News:Nine Healthcare Companies Named Finalists for Innovations in HealthcareSM ABBY Awards, to be Presented April 28th 2Health News:Nine Healthcare Companies Named Finalists for Innovations in HealthcareSM ABBY Awards, to be Presented April 28th 3Health News:Nine Healthcare Companies Named Finalists for Innovations in HealthcareSM ABBY Awards, to be Presented April 28th 4Health News:Nine Healthcare Companies Named Finalists for Innovations in HealthcareSM ABBY Awards, to be Presented April 28th 5Health News:Long Island Pediatric Group Announces Policy Changes That Will Help More New Yorkers 2Health News:Long Island Pediatric Group Announces Policy Changes That Will Help More New Yorkers 3Health News:TechWorld Medicals NasalCare Nasal Cleanse Kit Named “Best New Product” at ECRM Cough & Cold and Allergy Conference 2Health News:TechWorld Medicals NasalCare Nasal Cleanse Kit Named “Best New Product” at ECRM Cough & Cold and Allergy Conference 3
(Date:8/29/2014)... 29, 2014 Research and Markets ... Cancer Therapeutics Market & Pipeline Insight 2014" report ... developed to prevent and eradicate the prevalence of cancer ... are confined to low specificity, safety and large number ... for a better solution. It has been discovered that ...
(Date:8/29/2014)... Aug. 29, 2014  United Therapeutics Corporation (NASDAQ: ... Court for the District of New Jersey ... company,s case against Sandoz, Inc. regarding United Therapeutics, Remodulin ... ruled that U.S. Patent No. 6,765,117 is both ... from marketing its generic product until the expiration of ...
(Date:8/29/2014)... -- ChemImage will present a workshop focused on hyperspectral ... Science Society,s 22 nd International Symposium on ... .  Forensic Scientists will be in attendance ... can bring to examination procedures. ... Development at ChemImage, will host a workshop during ...
Breaking Medicine Technology:Global Peptide Cancer Therapeutics Market & Pipeline Insight 2014 2District Court Decision Received In Remodulin Patent Case 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 3
... , LARGO, Fla., Dec. 22 Unilens Vision Inc. ... that the shareholders of Unilens Vision Inc. voted overwhelmingly in ... at the extraordinary general meeting of its shareholders held yesterday. ... common shares (or 48.9%) were voted at the meeting with ...
... , HONG KONG, Dec. 22 /PRNewswire-Asia/ ... human health in a pioneering medical,field. On Dec. 20, 2009, ... Conference of Endoscopic Physicians. It,s been an honor,to have him ... benefiting human health. , "Endoscopic medicine ...
Cached Medicine Technology:Unilens Announces Extraordinary Meeting Results 2Olympic Winner Xiong Ni, Spokesperson for Endoscopic Medicine -- Chinese Minimally Invasive Advanced Technology Top in the World 2Olympic Winner Xiong Ni, Spokesperson for Endoscopic Medicine -- Chinese Minimally Invasive Advanced Technology Top in the World 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: